A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
a study on Myelofibrosis Leukemia Myeloproliferative Neoplasms Myelodysplastic Syndrome Preleukemia Primary Myelofibrosis Myeloproliferative Disorders Bone Marrow Disease Hematologic Disease Precancerous Conditions Neoplasms Essential Thrombocytosis Essential Thrombocythemia
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
- Principal Investigator
- by Gary Schiller (ucla)
Description
Summary
Phase 1 Part (Complete): Open-label, sequential dose escalation study of pelabresib in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis.
Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis.
CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Official Title
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis and Essential Thrombocytopenia)
Keywords
Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic Syndrome (MDS), Preleukemia, Primary Myelofibrosis, Myeloproliferative Disorders, Bone Marrow Disease, Hematological Disease, Precancerous Conditions, Neoplasms, Leukemia, Neoplasms by Histologic Type, Essential Thrombocytosis, Phase 1, Phase 2, Oncology, BET Inhibitor, Ruxolitinib, Pelabresib, Myeloid Leukemia, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Hematologic Diseases, Bone Marrow Diseases, Thrombocytosis, Essential Thrombocythemia, Pelabresib (CPI-0610)
Eligibility
You can join if…
Open to people ages 18 years and up
Phase 2 part: Patients with confirmed diagnosis of MF who meet all of the following criteria:
- ANC ≥ 1 x 109/L without the assistance of granulocyte growth factors
- Peripheral blood blast count <10%
- ECOG performance status ≤ 2.
- Adequate hematological, renal, hepatic, and coagulation laboratory assessments
- No prior treatment with a BET inhibitor
- Patients must give written informed consent to participate in this study before the performance of any study-related procedure.
For Arm 1 and 2 the following criteria should be considered:
- Patients with confirmed diagnosis of MF who meet all of the following criteria
- Dynamic International Prognostic Scoring System (DIPSS) risk category of intermediate-2 or higher
- Spleen volume ≥ 450 cm3 by MRI or CT for Cohorts 1B and 2B OR RBC transfusion dependent (defined as an average of ≥2 units of RBC transfusions per month (total of greater than 6 RBC transfusions) over the 12 weeks prior to enrollment for Cohorts 1A and 2A)
- At least 2 symptoms measurable (Score ≥ 1) using the Myelofibrosis Symptom Assessment Form Version 4.0 (MFSAF v4.0)
- Platelet count ≥ 75 x 109/L without the assistance of thrombopoietic factors or transfusions for at least 14 days
- Arm (Arm 1): Previously treated with a JAK inhibitor and be intolerant, resistant, refractory, or lost response to the JAK inhibitor; have not received the JAK inhibitor within 2 weeks prior to the start of study drug, or are ineligible to be treated with a JAK inhibitor
- Combination Arm (Arm 2): Must have received single agent ruxolitinib and be on a stable dose for a minimum 8 weeks but have disease that is not being adequately controlled by ruxolitinib
For Arm 3 (JAK inhibitors naïve) the following criteria should be considered:
- Patients with confirmed diagnosis of MF who meet all of the following criteria
- Dynamic International Prognostic Scoring System (DIPSS) risk category of intermediate-2 or higher
- Platelet count ≥ 100 x 109/L without the assistance of thrombopoietic factors or transfusions
- Spleen volume ≥ 450 cm3 by MRI/CT
- At least 2 symptoms measurable (Score ≥ 3) or a total score of ≥ 10 using the Myelofibrosis Symptom Assessment Form Version 4.0 ( MFSAF v4.0)
- No prior treatment with JAKi allowed
For Arm 4 (ET Expansion) the following criteria should be considered:
- Patients with a confirmed diagnosis of ET
- High-risk disease, defined as meeting at least one of the following criteria:
- Age > 60 years
- Platelet count > 1500 × 109/L (at any point during the patient's disease)
- Previously documented thrombosis, erythromelalgia, or migraine
- Previous hemorrhage related to ET
- Diabetes or hypertension requiring pharmacological therapy for > 6 months
- Have ≥2 symptoms with an average score ≥ 3 over the 7-day period prior to Cycle 1 Day 1 or an average total score of ≥15 over the 7-day period prior to Cycle 1 Day 1 using the using the MPN SAF
- Platelets > 600 × 109/L
- Resistant or intolerant to HU
You CAN'T join if...
- Current known active or chronic infection with human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C.
- Impaired cardiac function or clinically significant cardiac diseases
- Patients with Child-Pugh Class B or C
- Impairment of gastrointestinal (GI) function or GI disease that could significantly alter the absorption of pelabresib and/or ruxolitinib, including any unresolved nausea, vomiting, or diarrhea that is CTCAE Grade >1
- Prior treatment with a BET inhibitor.
- Pregnant or lactating women
- Any other concurrent severe and/or uncontrolled concomitant medical condition that could compromise participation in the study
- Patients unwilling or unable to comply with this study protocol.
Locations
- UCLA Medical Center
Los Angeles California 90095 United States - Mayo Clinic Arizona
Phoenix Arizona 85054 United States
Lead Scientist at University of California Health
- Gary Schiller (ucla)
Professor-in-Residence, Medicine. Authored (or co-authored) 160 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Constellation Pharmaceuticals
- ID
- NCT02158858
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- About 336 people participating
- Last Updated